CR20210363A - Análogos de péptidos de canotoxina y usos para el tratamiento del dolor y de las afecciones inflamatorias - Google Patents

Análogos de péptidos de canotoxina y usos para el tratamiento del dolor y de las afecciones inflamatorias

Info

Publication number
CR20210363A
CR20210363A CR20210363A CR20210363A CR20210363A CR 20210363 A CR20210363 A CR 20210363A CR 20210363 A CR20210363 A CR 20210363A CR 20210363 A CR20210363 A CR 20210363A CR 20210363 A CR20210363 A CR 20210363A
Authority
CR
Costa Rica
Prior art keywords
peptide analogs
conotoxin peptide
treatment
pain
inflammatory conditions
Prior art date
Application number
CR20210363A
Other languages
English (en)
Inventor
Shawn Iadonato
Jeffrey J Posakony
Jose Mercado
Eric J Tarcha
Original Assignee
Kineta Chronic Pain Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kineta Chronic Pain Llc filed Critical Kineta Chronic Pain Llc
Publication of CR20210363A publication Critical patent/CR20210363A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se proporcionan análogos de péptidos de alfa-conotoxina, los cuales incluyen a los análogos de péptidos de alfa-conotoxina que se unen de una forma covalente al polietilen glicol (PEG), y composiciones farmacéuticas de tales análogos de péptidos de alfa-conotoxina. También se proporcionan en este documento los métodos para tratar o prevenir una afección propicia para el tratamiento o la prevención por medio de la inhibición de un receptor de acetilcolina nicotínico (nAChR) que contiene α9 (por ejemplo, el subtipo α9α10 del nAChR) en un sujeto
CR20210363A 2019-01-04 2019-01-04 Análogos de péptidos de canotoxina y usos para el tratamiento del dolor y de las afecciones inflamatorias CR20210363A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/012307 WO2020142102A1 (en) 2019-01-04 2019-01-04 Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions

Publications (1)

Publication Number Publication Date
CR20210363A true CR20210363A (es) 2021-12-10

Family

ID=65244618

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210363A CR20210363A (es) 2019-01-04 2019-01-04 Análogos de péptidos de canotoxina y usos para el tratamiento del dolor y de las afecciones inflamatorias

Country Status (15)

Country Link
EP (1) EP3906253A1 (es)
JP (1) JP2022522935A (es)
KR (1) KR20210116505A (es)
CN (1) CN113966339A (es)
AU (1) AU2019418319A1 (es)
BR (1) BR112021013302A2 (es)
CA (1) CA3125383A1 (es)
CL (1) CL2021001775A1 (es)
CO (1) CO2021008845A2 (es)
CR (1) CR20210363A (es)
IL (1) IL284574A (es)
MX (1) MX2021008070A (es)
PE (1) PE20211734A1 (es)
SG (1) SG11202106847SA (es)
WO (1) WO2020142102A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230033485A (ko) 2021-09-01 2023-03-08 삼성전자주식회사 저장 장치 및 그의 동작 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717775B2 (en) * 2006-07-18 2017-08-01 University Of Utah Research Foundation Methods for treating pain and screening analgesic compounds
US9284358B2 (en) 2006-07-18 2016-03-15 University Of Utah Research Foundation Conotoxin peptides
WO2009126292A2 (en) * 2008-04-08 2009-10-15 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
EP3215172B1 (en) 2014-11-07 2023-04-26 Kineta Chronic Pain, Llc. Modifications and uses of conotoxin peptides

Also Published As

Publication number Publication date
MX2021008070A (es) 2021-10-13
WO2020142102A9 (en) 2020-11-19
PE20211734A1 (es) 2021-09-06
WO2020142102A1 (en) 2020-07-09
CN113966339A (zh) 2022-01-21
CA3125383A1 (en) 2020-07-09
SG11202106847SA (en) 2021-07-29
EP3906253A1 (en) 2021-11-10
CO2021008845A2 (es) 2021-10-29
AU2019418319A1 (en) 2021-07-22
KR20210116505A (ko) 2021-09-27
JP2022522935A (ja) 2022-04-21
CL2021001775A1 (es) 2022-05-27
BR112021013302A2 (pt) 2021-09-14
IL284574A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
SA519402217B1 (ar) مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون
JOP20200055A1 (ar) مركبات بيرازولو بيريميدينون واستخداماتها
MX2020001732A (es) Tratamiento de las afecciones del sistema nervioso central.
MX2018003331A (es) Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados.
PH12020551425A1 (en) Rimegepant for cgrp related disorders
MX2019012884A (es) Terapia de combinacion.
MX2020007040A (es) Composiciones que comprenden microbiota coseleccionada y metodos para su uso.
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
MX2022002196A (es) Composición de liberación retardada de niclosamida y uso antiviral de la misma.
MX2021010144A (es) Formulaciones farmaceuticas.
MX2019005104A (es) Composiciones de zinc-y-pga y métodos para tratar el cancer.
MX2023009976A (es) Compuestos de pladienolida y su uso.
MX2015016492A (es) Peptidos de y conotoxina, composicion farmaceutica y usos de los mismos.
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
MX2019011908A (es) Macrociclos de peptidos anti-bacterianos y uso de los mismos.
RU2016137289A (ru) Схема применения соединения fgf-18
CR20210363A (es) Análogos de péptidos de canotoxina y usos para el tratamiento del dolor y de las afecciones inflamatorias
EA201991531A1 (ru) Способы лечения композициями линаклотида с отсроченным высвобождением
MX2019012522A (es) Compuestos y metodos terapeuticos.
MX2021011986A (es) Metodos de tratamiento de dolor neuropatico.
MX2021006654A (es) Uso de extracto de cocculus hirsutus para tratar dengue.
EA202092190A1 (ru) Композиции и способы для лечения сильного запора
WO2019241306A3 (en) Combination therapy with neoantigen vaccine
TW201129361A (en) Methods for treating pain